11 June 2025 Highlights • Olympus Corporation, one of the world’s largest medical device companies, launches a new campaign for SeleCT™ Screening across the United States
• SeleCT™ Screening uses 4DMedical’s lung density analysis technology on existing CT scans to identify candidates for the Olympus Spiration™ Valve System
• Full market release by Olympus creates large-scale U.S. deployment of 4DMedical’s AI-based lung imaging for therapeutic screening
The share price is not reflecting the CEOs cheerie confidence! ...normal ..hehe
see how this opens..
30.0¢
Change
0.000(0.00%)
Mkt cap !
$139.6M
4DX on the move!
https://hotcopper.com.au/threads/ann-4dmedical-files-fda-submission-for-ctvq.8597580/
4DMedical files FDA 510(k) submission for CT:VQ™, a non-contrast CT-based lung imaging software product for assessing both ventilation (V) and perfusion (Q) in the lungs
• CT:VQ™ represents a revolution in ventilation perfusion imaging, solving key clinical and logistical limitations across all forms of nuclear ventilation perfusion imaging
• Compelling clinical validation package, demonstrating equivalence (or superiority) to SPECT ventilation perfusion across multiple lung conditions
• 4DMedical expects to capture 100% of the one million nuclear ventilation perfusion scans performed annually
• CT:VQ™ is expected to align with the Company’s existing CT LVAS™ CPT code (USD $650), supporting rapid clinical adoption
• Provides the potential to grow the current ventilation perfusion market into new applications in disease monitoring and screening, due to the wide availability of CT infrastructure
• When including days spent with the applicant, the average time for FDA 510(k) decision is approximately 120 days
• 4DMedical will hold an investor webinar tomorrow, Tuesday 27 May 2025 at 11am AEST
Investor Webinar 4DMedical will hold an investor webinar tomorrow, Tuesday 27 May 2025 at 11am AEST, where Dr Andreas Fouras will provide further information, and host a Q&A session, in relation to CT:VQ™. Please register in advance using the following links: Phone registration: https://s1.c-conf.com/diamondpass/10047546-qpjld5.html Webcast: https://ccmediaframe.com/?id=a2ozxVzA After registering, you will receive a confirmation email containing information about joining the webinar or dial-in details for those who would prefer to join by telephone.
Last
30.5¢
Change
0.045(17.3%)
Mkt cap !
$137.4M
The SPP and Placement combined raised $45 million (before costs) and is being deployed to strengthen and accelerate the Company’s commercialisation strategy.
Life support for of $1.1M - 4DX will have to grow profitability eventually though.....
We are extremely excited to have been awarded the $1.1 million CTCM funding announced today. Combining both functional components of airflow and blood flow into a single analytical process represents a dramatic advancement in respiratory healthcare, providing the ideal test for phenotyping, early detection and evaluation of specific treatment responses for high-impact lung diseases such as Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis, pulmonary hypertension and pulmonary embolism.
A total of 28,044,096 fully paid ordinary shares New Shares will be issued to SPP applicants at an issue price of $0.89 per New Share. The New Shares issued will represent 8.1% of 4DMedical’s issued capital and will rank equally with existing shares on issue from their date of issue.
The New Shares issued under the SPP are expected to be allotted on Wednesday, 31 May 2023 and are
expected to commence trading on ASX on Thursday, 1 June 2023. The total funds raised, comprising the Placement ($20m) and SPP ($25m), amount to $45m (before costs).
Proceeds raised under the Placement and SPP will be used primarily to accelerate commercialisation of 4DMedical's respiratory imaging software and significantly strengthen the Company's balance sheet. Funds raised leave the Company with a cash balance of approximately $79.6m after costs as at 31 March 2023 on a proforma basis
Fouras - CEO (2012) circa 23% voting power.
1 Month ago 4DMedical (ASX:4DX) signs first US hospital SaaS contract https://youtu.be/ef8j0lr2JUI
Dr Andreas Fouras
Chief Executive Officer,Managing Director (Since 2012)
Bio
Dr Fouras is the founder, Managing Director and Chief Executive Officer (CEO) of the Group. He is also the Groups Chief Technology Officer being the inventor of its core XV Technology, maintaining a direct role in its evolution and development. Andreas career in academic research has a foundation gained within the Department of Mechanical and Aerospace Engineering at Monash University in Melbourne, Australia. This research into wind tunnel quantification garnered recognition as a young leader in the scientific discipline of fluid dynamics, developing a number of new approaches to the imaging of gas and liquid flow. Following completion of a Masters degree by research and a Doctorate (PhD), Andreas rapidly rose to the position of Professor of Mechanical and Aerospace Engineering and Director of the Laboratory for Dynamic Imaging.
He received accolades from a wide range of premier research bodies including the National Health and Medical Research Council (NHMRC) and the American Asthma Foundation. Andreas applied a novel concept to clinical use through the development of XV Technology, uniquely measuring airflow within the breathing lungs at every stage of the breath, providing both high spatial and temporal resolution at very low dose.
This research has been documented in over 100 peer reviewed publications and resulted in 72 patent applications with 40 granted. In December 2012, Andreas founded 4DMedical resulting from a deeply held personal and professional desire for his work to reach and positively influence as many people afflicted by respiratory compromise as possible, through global clinical translation.
Andreas leadership is evidenced as a commissioned officer in the Australian Army (Infantry) and through the prestigious Australian Davos Connections Australian Leadership Award for 2013. The focus of Andreas substantial intellect and energy is now concentrated upon applying business acumen, drive and innovation to the successful commercialisation of 4DMedicals technologies. Andreas is a member of the Medical Advisory Committee.
